Novo Nordisk to Cut U.S. Prices for Ozempic and Wegovy

Novo Nordisk announced plans to reduce the U.S. list prices for its popular diabetes and weight-loss drugs, Ozempic and Wegovy, by up to 50%. This move aims to make the medications more affordable for patients.